Off-Label Photodynamic Therapy Coverage Extended To AMD Population
This article was originally published in The Gray Sheet
Executive Summary
Clinical trial subgroup analyses showing the ability of lesion size to predict patient benefit helped convince CMS to expand national Medicare coverage of QLT/Novartis' Visudyne (verteporfin)